Back to Results

A Phase 1/2, Open-Label, Dose-Escalation and Expansion study of Entrectinib (RXDX-101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or Who Have No Satisfactory Treatment Options

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Child

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Margaret Macy,  MD

Margaret Macy, MD

Study ID

Protocol Number: 16-0749

More information available at ClinicalTrials.gov: NCT02650401

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers